COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients

COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL‐6R) antagonist therapy for the COVID‐19 patients. Two humanized monoclonal antibodies are in clini...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Med Virol
Auteurs principaux: Chakraborty, Chiranjib, Sharma, Ashish Ranjan, Bhattacharya, Manojit, Sharma, Garima, Lee, Sang‐Soo, Agoramoorthy, Govindasamy
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Commentary
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7283789/
https://ncbi.nlm.nih.gov/pubmed/32462717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.26078
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires